Axsome Therapeutics, Inc. (AXSM) said, based on preliminary financial information, Axsome expects total product revenue to be approximately $196.0 million for the fourth quarter, representing 65% annual growth compared to the fourth quarter 2024. The company expects total product revenue of approximately $638.5 million for the full year 2025, representing 66% annual growth compared to the full year 2024.
The company noted that AUVELITY net product sales are expected to be approximately $155.1 million and $507.1 million for the fourth quarter and full year 2025, respectively.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.